AVANOS MEDICAL, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated cash flow statements

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating Activities
Net loss
Depreciation and amortization
Stock-based compensation
Asset impairments
Net losses on asset dispositions
Goodwill and intangibles impairment
Loss on RH disposal
Net losses on asset dispositions and asset impairments
Changes in operating assets and liabilities, net of acquisition
Accounts receivable
Inventories, net of allowance
Prepaid expenses and other assets
Accounts payable
Accrued expenses
Deferred income taxes and other
Cash Provided by Operating Activities

Investing Activities
Capital expenditures
Proceeds from the sale of assets
Proceeds from the RH divestiture
Proceeds from RH divestiture post-closing settlement
Acquisition of assets and businesses, net of cash acquired
Acquisition of minority interest investment
Investments in non-affiliates
Cash (Used in) Provided by Investing Activities

Financing Activities
Proceeds from issuance of secured debt
Secured debt repayments
Debt issuance costs
Revolving credit facility proceeds
Revolving credit facility repayments
Purchase of treasury stock
Proceeds from the exercise of stock options
Payment of contingent consideration liabilities
Cash Used in Financing Activities
Effect of Exchange Rate Changes on Cash and Cash Equivalents
(Decrease) Increase in Cash and Cash Equivalents
Cash and Cash Equivalents - Beginning of Year
Cash and Cash Equivalents - End of Year
Supplemental Cash Flow Disclosure:
Cash refund for income taxes
Cash paid for income taxes
Cash paid for interest

Supplemental Noncash Disclosure
Capital expenditures included in accounts payable or accrued expenses

Comments